Harrow Inc. (NASDAQ:HROW) shares are down during Tuesday’s premarket session as the company faces scrutiny following its recent financial results announcement.
The eye disease medicine maker, Harrow, reported fourth quarter earnings of 17 cents per share, missing the consensus estimate of 38 cents.
Sales jumped from $66.81 million to $89.09 million, beating the consensus of $88.45 million.
During the fourth quarter and full-year ended December 31, 2025, Harrow recorded $8.5 million in acquired in-process research and development expenses related to its acquisition of Melt Pharmaceuticals.
In a shareholder letter on Monday, the company wrote, “…some readers may be aware that the U.S. Securities and Exchange Commission requires us to include a five-year stock performance graph of our cumulative total stockholder return in our annual report. I view the graph below as a powerful reminder of how far Harrow has come in a relatively short period, with Harrow’s stock price increasing by more than 700% over the past five years.”